Description:
(abstract)Inosine pranobex (InP), an immunomodulatory drug approved for clinical use worldwide, is a potential adjuvant for cancer vaccines with a low clinical translation barrier. However, the administration of soluble InP agents in free format is associated with drawbacks of a short half-life period and limited efficacy. In this study, a rapid self-assembly approach was proposed for the synthesis of cancer vaccines due to the coordination interaction of ferric ion and acedoben (Ace) in InP. The self-assembled cancer vaccines can be readily adjusted from the microscale to the nanoscale, with shapes including rods, fibers, and spheres. Herein, Fe-Ace coordination complexes not only serve as carriers for tumor antigens, but also enhance antigen-specific antitumor immunity due to their intrinsic adjuvant properties. Nanofibrous self-assembled cancer vaccines based on Fe-Ace coordination complexes more effectively induced an antitumor immune response, exerted a remarkable therapeutic effect, and inhibited the tumor growth at distant site in vivo, compared to free InP and other self-assembled cancer vaccines. The presented work provides a promising strategy for the rapid manufacture of InP-derived self-adjuvant, self-carrier, and self-assembled vaccines for cancer immunotherapy.
Rights:
© 2024. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
Keyword: cancer immunotherapy, therapeutic cancer vaccines, coordination complexes, inosine pranobex, self-assembly
Date published: 2024-06-26
Publisher: Elsevier BV
Journal:
Funding:
Manuscript type: Author's version (Accepted manuscript)
MDR DOI: https://doi.org/10.48505/nims.4760
First published URL: https://doi.org/10.1016/j.apmt.2024.102299
Related item:
Other identifier(s):
Contact agent:
Updated at: 2024-09-19 11:56:10 +0900
Published on MDR: 2026-06-26 08:27:44 +0900
| Filename | Size | |||
|---|---|---|---|---|
| Filename |
APMT -著者最終稿.pdf
(Thumbnail)
application/pdf |
Size | 4.08 MB | Detail |